Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Osivax

News headline image
Osivax Secures Strategic Funding to Accelerate the Development of its Influenza Vaccine Candidates
From Osivax
Via Business Wire
News headline image
Osivax Announces First Participant Vaccinated in Phase 2a Clinical Booster Trial of Influenza Vaccine Candidate OVX836
From Osivax
Via Business Wire
News headline image
Osivax and KM Biologics Enter Exclusive License Option Agreement for Broad-Spectrum “Universal” Influenza Vaccine in Japan
From Osivax
Via Business Wire
News headline image
Osivax Completes Enrollment for Phase 1 Trial with Broad-Spectrum Sarbecovirus Vaccine Candidate, OVX033
From Osivax
Via Business Wire
News headline image
Osivax Announces Vaccination of Last Patient in Phase 2a Clinical Trial Evaluating OVX836 Combined with QIVs
From Osivax
Via Business Wire
News headline image
Osivax Announces Vaccination of First Participant in First-in-Human Trial Evaluating Sarbecovirus Vaccine Candidate OVX033
From Osivax
Via Business Wire
News headline image
Osivax Appoints Dr. Nicola Groth as Chief Medical Officer
From Osivax
Via Business Wire
News headline image
Osivax Receives Over USD 1.5M Grant from NIAID to Advance Development of Broad-Spectrum Influenza Vaccine Candidate, OVX836
From Osivax
Via Business Wire
News headline image
Osivax Announces Publication in The Lancet Infectious Diseases of Phase 2a Data for Broad-Spectrum Influenza Vaccine Candidate, OVX836
From Osivax
Via Business Wire
News headline image
Osivax Publishes Preclinical Data for Sarbecovirus Vaccine Candidate, OVX033 in Frontiers in Immunology
From Osivax
Via Business Wire
News headline image
Osivax Announces Vaccination of First Participant in Phase 2a Clinical Trial Evaluating OVX836 Combined with QIVs
From Osivax
Via Business Wire
News headline image
Osivax Awarded Grant from a Leading Non-Governmental Organization for OVX836, its Broad-Spectrum Influenza Vaccine
From Osivax
Via Business Wire
News headline image
Osivax Appoints Dr. Chris Martin, Renowned Biotech Entrepreneur, to its Board of Directors
From Osivax
Via Business Wire
News headline image
Osivax Announces Last Patient Last Visit in Two Phase 2a Clinical Trials with Broad-Spectrum Influenza Vaccine Candidate OVX836
From Osivax
Via Business Wire
News headline image
Osivax Appoints Vincent Bille as Chief Manufacturing Officer and Announces Manufacturing Progress for OVX836
From Osivax
Via Business Wire
News headline image
Osivax Announces Clinical and Preclinical Vaccine Data Presentations at Upcoming Global Influenza Conferences
From Osivax
Via Business Wire
News headline image
Osivax Secures EUR 10M Grant from Bpifrance to Support Clinical Development of OVX836, a Broad-Spectrum Influenza Vaccine
From Osivax
Via Business Wire
News headline image
Osivax Provides Clinical Development Update on Lead Influenza Vaccine Candidate OVX836
From Osivax
Via Business Wire
News headline image
Osivax Enters Research Collaboration with the NIAID for the Evaluation of Combination Approach to Broad-Spectrum Influenza Vaccines
From Osivax
Via Business Wire
News headline image
Osivax Announces Publication of Phase 2a Trial Results for Influenza Vaccine Candidate OVX836 in Frontiers in Immunology
From Osivax
Via Business Wire
News headline image
Osivax Appoints Dr. Michael Watson, Former President of Moderna Vaccine Division, to Its Board of Directors
From Osivax
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.